Apc mutation is accompanied by increased EGFR expression and activity in the tumors, which explains the efficacy of EGFR-targeting therapeutics in the treatment of colorectal cancer patients of specific molecular subtypes [50,51,52]. Here, EGFR is linked to colorectal cancer.